City briefs: Surgical Innovations; Tissue Regenix; and more

Surgical Innovations Group, a medical technology business, says its wholly owned subsidiary, Elemental Healthcare, has launched a new biological matrix range for Breast Reconstruction, manufactured by Meccellis.

Cellis Breast is a comprehensive range of biological matrices for Breast Reconstruction which received their CE mark in April 2020.

Trials were delayed as a consequence of the NHS response to Covid-19. However, with the resumption in some hospitals of breast reconstruction, evaluations have been successfully carried out which has mean the company has met its quarter four target for UK market launch of the product.

Elemental’s Project Management team worked with key surgeons at selected hospitals to understand optimal practice and techniques.

The UK market for biological matrices for breast reconstruction is worth approximately £16m and Cellis Breast is well placed to gain market share as reconstructive surgery resumes following deferrals due to Covid-19.

Adam Power, Elemental MD and group development director at Leeds-based Surgical Innovations, said: “Elemental have worked closely with Meccellis over the last three years during the development of Cellis Breast and we are excited that we now have a range of products that are well designed and competitively priced which will enable us to compete well in this market.”

Anthony Peres, CEO of Meccellis, added: “The UK is one of the largest markets in the world for the use of biological matrix products in immediate breast reconstruction following cancer surgery. 

“Meccellis now has a full range of products for this procedure that are both innovative and cost effective.

“Following the successful evaluations, we are now looking forward to the further success of our partner, Elemental Healthcare, in growing UK sales.”

:::

Leeds-based regenerative medical devices company, Tissue Regenix Group, has announced its first delivery of the OrthoPure® XT product has taken place, with additional shipments expected in early 2021.

OrthoPure® XT is a decellularized porcine tendon, developed using the Group’s patented dCELL® technology. It was granted CE Mark approval in June 2020 for the reconstruction of knee ligaments to restore function and stability.

In August 2020, Tissue Regenix confirmed its first distribution agreement, focused on the UK market, with a speciality supplier of orthopaedic and biologic products.

The Group has since targeted key European markets including securing an additional distribution partner in Poland.

It is currently engaged in a number of discussions with potential partners in other regions.

Daniel Lee, chief executive officer, Tissue Regenix Group, said: “Our plan is to establish an initial distribution network for OrthoPure® XT and expand as procedural levels return.

“This will be a key product for the Group in Europe and highlights the need, and demand, for biologic solutions outside of the current US market.

“It is a testament to the work of our processing and commercial teams that we have secured distribution agreements and delivery of the product has remained on-track despite the challenges presented during 2020.”

:::

Live data company WANdisco says its existing relationship with IBM has been extended to integrate WANdisco’s own LiveData Migrator product into IBM’s Big Replicate solution.

LiveData Migrator will allow IBM customers to seamlessly migrate on-premise data to hybrid cloud and multi-cloud infrastructures.

IBM Big Replicate already features WANdisco’s patented LiveData Plane technology, which enables data consistency within distributed environments to help clients keep unstructured data accessible, accurate and consistent.

Sheffield-based WANdisco has been collaborating with IBM for four years on various technologies.

It notes that it is pleased IBM Big Replicate customers will now have the complete freedom to choose where their data lives within their enterprises’ IT infrastructure.

David Richards, CEO and co-founder of WANdisco, said: “We have been working successfully with IBM for four years and it is exciting to see our partnership evolve to encompass LiveData Migrator, our latest product, and provide IBM customers with the ability to start moving data at petabyte-scale to the cloud in minutes.”

 Holly Vatter, senior global solutions, product marketing manager at IBM, said: “Keeping data consistent in a distributed environment whether on-premise, hybrid or multi-cloud, across platforms or regions is a challenge that IBM Big Replicate LiveData Migrator was built to handle.

“Powered by a high-performance coordination engine, it uses consensus to keep unstructured data accessible, accurate and consistent regardless of the environment.”

Click here to sign up to receive our new South West business news...
Close